This study evaluated the effects of chronic treatment with cabergoline (CAB), a new, potent and longlasting ergoline-derived dopamine agonist, on seminal¯uid parameters and sexual and gonadal function in hyperprolactinemic males in comparison with the effect of bromocriptine (BRC) treatment.
Introduction
The impairment of gonadal function is the most common clinical ®nding of hyperprolactinemia in both sexes. In particular, elevated prolactin (PRL) levels were shown in about 1±5% of oligospermic men without demonstrable pituitary tumors (1, 2) . In the last two decades it has been widely demonstrated that the medical treatment of hyperprolactinemia with dopamine agonists normalizes serum PRL levels and reduces tumoral mass, so restoring gonadal and sexual function in most patients (3±9). However, in the world literature, data on semen analysis in hyperprolactinemic patients during dopamine agonist treatment are lacking. In a recent study we showed that a 1-year treatment with CV 205±502 normalized serum PRL levels and restored gonadal function with disappearance of libido impairment and of several functional abnormalities of the ejaculates (10). This result is apparently in disagreement with another study reporting the lack of signi®cant change in seminal¯uid parameters during bromocriptine (BRC) therapy (3). However, no signi®cant change in seminal¯uid parameters, except an increase in sperm count, was found during the ®rst months of CV 205±502 therapy, in spite of suppressed PRL concentrations. This indicated that a long period of treatment is required to restore the gonadal function in hyperprolactinemic males. Cabergoline (CAB), a synthetic ergoline which is a selective and long-lasting D 2 dopamine agonist that inhibits PRL secretion both in healthy and hyperprolactinemic subjects, has been recently introduced into the therapeutic armamentarium for hyperprolactinemic syndromes. CAB is characterized by a duration of action as long as 21 days after a single oral dose of 0.3±1 mg (11±14). Moreover, CAB has been shown to be more effective and better tolerated than BRC in a multicenter, randomized 24-week trial in 459 hyperprolactinemic women (15) and in a few patients with macroprolactinoma (16) .
Since CAB was shown to notably reduce prolactinoma volume (17, 18) , and was even effective in prolactinomas resistant to BRC and CV 205±502 (19) , this study was designed to evaluate whether chronic treatment with CAB could successfully restore gonadal and sexual function in males with macroprolactinoma, and the time-course of this effect. To this end, the results of CAB treatment were compared with those obtained using BRC in a similar group of patients. Moreover, since hyperprolactinemic males suffer from de®ciency of libido and potency, though not always reaching complete impotence, their nocturnal penile tumescence (NPT) records were obtained.
Patients and methods

Patients
Among 26 males admitted to our Department for hyperprolactinemia from 1993 to 1996, 17 (aged 22± 38 years) with macroprolactinoma gave their informed consent to participate in this open-label study. All the patients suffered from libido impairment for at least 6± 12 months, and ten from reduced sexual potency; six had infertility and in ®ve provocative bilateral galactorrhea was recorded. Visual impairment was present in four patients. Because of different drug availabilities during recent years, ten were treated with BRC for 6 months while the remaining seven patients were treated with CAB. Four of seven CAB-treated patients (nos 1±3 and 5, Table 1 ) were previously treated also with BRC for a few days (less than 2 weeks) but the drug was withdrawn because of side-effects. Table 1 summarizes patient pro®les at study entry.
Study protocol
All of the patients were subjected to a clinical examination with ECG and complete blood and urine analysis. Serum PRL levels, assessed in multiple sampling over 6 h (0800±1400 h), and follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone and dihydrotestosterone (DHT) concentrations were assayed before and after 15, 30, 60, 90 and 180 days of CAB or BRC treatment. Semen and NPT analysis were carried out before and after 30, 90 and 180 days of CAB or BRC treatment.
Treatment protocol
The treatment with CAB was started at a dose of 0.5 mg once weekly for 15 days; afterwards the dose was increased to up to 0.5 mg twice weekly. Subsequently, on the basis of PRL values, the dose was increased to 1.5 mg/week in one patient (no. 2, Table 1 ) to achieve PRL level suppression. The treatment with BRC was started at a dose of 1.25 mg twice daily for 1 week, and then was increased to 2.5 mg twice daily for 3 weeks. Subsequently, on the basis of PRL values, the dose was increased to 10 mg/day in four patients (nos 1, 7, 8, 10, Table 1 ), and to 15 mg/day in one patient (no. 6, Table 1 ) to achieve PRL level suppression.
Methods
PRL, FSH, LH, testosterone and DHT levels were assessed by RIA using available commercial kits. Seminal¯uid evaluation was performed after at least 3 days of abstinence, and at least twice at study entry in line with guidelines of a World Health Organization (WHO) laboratory manual (18) . The evaluation of number and motility of the spermatozoa was carried out in a Makler Counting Chamber (´40); the morphology was analyzed after dilution (1:1) with PBS and Giemsa stain. Moreover, some functional sperm tests, such as the eosin test (ET), the hyposmotic swelling test (HOS) and the cervical mucus penetration test (CMPT), were performed as reported elsewhere (19) . The normal ranges of hormone levels, and sperm patterns according to the WHO manual (18) , are reported in the footnote to Table 2 .
The erectile capability of our patients during both treatments was evaluated by NPT, using Rigiscan equipment provided by Dacomed (Minneapolis, USA) (20) . This device allows monitoring of the duration, frequency and degree of both rigidity and tumescence during sleep. We performed three tests during three different nights; the best record was used for this study. As according to the literature (21), we considered normal one episode of rigidity over the 70% for almost 10 min with a variation of tumescence of 30 mm at the base and of 20 mm at the tip of penis. As far as frequency was concerned, three episodes per night were considered as the lowest normal value.
Radiological examinations
The computed tomography (CT) scan was carried out by a third generation scanner with 3.5 s acquisition times, 1.5 mm thickness axial and coronal sections, and Table 1 Clinical, hormone and radiological data of the 17 males with prolactinoma during treatment with cabergoline or bromocriptine. scout-view. CT was performed before and after intravenous infusion of contrast medium. Magnetic resonance imaging (MRI) was carried out by a super conductive magnetic resonance (0.5 tesla) and super®cial coil in axial, coronal and sagittal sections. The acquisitions were spin echo with 1000 ms repetition time and 40±120 ms echo time of 21 ms. CT and/or MRI were carried out before and 6 months after CAB or BRC treatment. Prolactinoma shrinkage was considered signi®cant when a reduction in tumor size greater than 30% (with respect to baseline size) was documented at MRI or CT scan.
Visual ®eld examination was performed by Goldmann±Friedmann perimetry before and 6 months after treatment in patients with visual ®eld defects.
Statistical analysis
Data are shown as means 6 S.E.M. The results were analyzed by Student's t-test for paired data for intragroup analysis, and by ANOVA followed by the Newmann± Keuls test for intergroup analysis. Signi®cance was set at 5%.
Results
At study entry, no difference was found between CABtreated and BRC-treated patients as far as hormonal assessment and sexual and gonadal function were concerned ( Table 2 ). The long-term treatments with CAB and BRC normalized serum PRL levels in all patients, as shown in Fig. 1 . In both CAB-and BRC-treated groups, serum PRL levels signi®cantly and progressively decreased from baseline values of 925 6 522 mg/l and 1059 6 297 mg/l to nadir values of 7.6 6 2.3 mg/l and 16.3 6 1.8 mg/l respectively (Table  1) . However, the decrease of PRL levels was more rapid during CAB than during BRC treatment; in fact, after 1 month PRL levels were normalized in six of seven patients during CAB treatment (nadir 20.6 6 6.6 mg/l) and in only one patient during BRC treatment (nadir 256.3 6 115.1 mg/l, P < 0.005). At the end of 6 months of treatment all patients had normal PRL levels ( Fig. 1) . At study entry, serum testosterone and DHT levels were low in all patients, being lower than normal in 8 of 17 patients, and progressively and signi®cantly increased during both treatments (Figs 2 and 3) . In fact, serum DHT levels increased from 0.4 6 0.1 to 1.1 6 0.4 nmol/l (P < 0.001) after CAB treatment and from 0.37 6 0.06 to 1.17 6 0.04 nmol/l (P < 0.001) after BRC. Serum FSH and LH levels slightly increased during treatment; however, baseline and in-treatment levels were normal except in 4 of 17 patients with macroprolactinoma (data not shown).
All patients reported a remarkable improvement of sexual potency and libido after only the ®rst 2 months of CAB treatment. At clinical examination disappearance of galactorrhea was seen in all four patients after 3±6 months of treatment (Table 1 ). In both groups of EUROPEAN 
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Gonadal function in hyperprolactinemic males 289 Table 2 Hormone pro®les and seminal¯uid parameters (6 S.E.M.) at study entry in 17 males with macroprolactinoma who were to undergo chronic treatment with cabergoline or bromocriptine.
Cabergoline-treatment
Bromocriptine-treatment patients patients (n 7) (n 10)
Serum hormone levels PRL (mg/l) 925.7 6 522.6 1059.4 6 297.6 Testosterone (mg/l) 3.7 6 0.3 3.2 6 0.2 DHT (mmol/l) 0.40 6 0.10 0.37 6 0.06 FSH (IU/l) 6.5 6 1.8 5.9 6 2.1 LH (IU/l) 5.2 6 3.1 5.3 6 2.8
Seminal¯uid parameters Concentration (10 6 /ml) 5.8 6 0.2 6.1 6 0. Normal ranges: PRL 5±25 mg/l; testosterone 3.5±9 mg/l; DHT 0.4±1.6 mmol/l; FSH and LH 5± 18 IU/l; spermatozoa concentration > 20´10 6 ml; sperm motility at 1 h 53.8±74.6%; forward progression 33.2±67.6%; normal morphology >30%; viability >60%; HOS >60%; CMPT >30 mm; zinc >2.4 mmol/ejaculate; citric acid >52 mmol/ejaculate; acid phosphatase >200 U/ejaculate; fructose >13 mmol/ejaculate. patients, NPT analysis showed a signi®cantly reduced rigidity and tumescence of the penis at the beginning of treatment; after both treatments, rigidity and tumescence normalized in all patients (Table 3) .
Before treatment, the ejaculates showed decreased sperm count, motility, viability, and biochemical and functional patterns. During treatment a signi®cant increase of sperm count, motility, viability and functional activity was noted. In particular, the improvement of sperm count was observed after 3 months of CAB treatment and persisted until the 6th month. During BRC treatment sperm count, motility, viability and functional test remained unmodi®ed in the 1st month of therapy, but progressively increased after the 3rd month until the 6th month (Table 4) . Two patients fathered children during CAB treatment.
A signi®cant shrinkage of tumor mass was detected by CT scan and/or MRI in ®ve of seven patients (71.4%) treated with CAB and in six of ten (60%) treated with BRC. Improvement of the visual ®eld was noted in the patients with visual ®eld defects (Table 1) .
Lastly, side-effects were reported by two and seven patients at the beginning of CAB and BRC treatment respectively. During CAB treatment, side-effects were milder and shorter lasting, and did not require any speci®c treatment. Conversely, in two patients treated with BRC, the dose of BRC was reduced for a few days and thereafter progressively increased to therapeutic values. Two to three days of bed rest were required in two patients (nos 2 and 9) showing postural hypotension after drug administration at the beginning of BRC treatment.
Discussion
In recent years, CAB has been shown to be highly effective in normalizing serum PRL levels at low doses (11±16), with excellent patient compliance. Moreover, CAB was effective in patients with prolactinoma resistant to BRC and CV 205±502 (17) . However, although the recovery of gonadal function and fertility in females has been widely documented, no data had been reported so far on sexual and gonadal function in hyperprolactinemic males during CAB treatment. Thus, we evaluated whether CAB was able to restore gonadal function in a few hyperprolactinemic males, and the time-course of this result. In the present report, all seven patients treated with CAB showed a remarkable improvement of libido and potency, and an improvement in sperm parameters, after only 3 months of treatment, while in the ten patients treated with BRC sperm parameters improved later. On the other hand, serum PRL levels were normalized in all 17 patients, but normoprolactinemia was reached after 2 months in the seven patients treated with CAB and after 6 months in the ten treated with BRC. Moreover, in CAB-treated patients, the percentage of immature germ cells became signi®cantly reduced, while sperm viability, swollen tails and penetration in bovine cervical mucus signi®cantly increased during the ®rst 3 months of treatment. By contrast, the biochemical parameters of seminal¯uid were not signi®cantly changed.
The improvement of seminal¯uid analysis after longterm CAB treatment occurred fast in comparison to the notable results obtained after CV 205±502 treatment in a different series of patients (17) and to the results obtained after BRC treatment. This bene®cial effect of CAB could be due either to the peculiar pharmacokinetic pro®le of CAB, characterized by a prolonged halflife and a notably slow elimination from highly perfused tissues like the pituitary (22) or to the fact that in this series were included patients untreated or who had received BRC only for a few days. Therefore, these patients could better respond to the rapid serum PRL normalization. The positive effect of CAB treatment on gonadal and sexual function in hyperprolactinemic males is closely correlated to the effect played by PRL not only on sexual steroid secretion but also on spermatogenesis. In fact, it has been recently demonstrated that PRL receptors are present in all stages of the cycle of the seminiferous epithelium, the surface of Leydig and Sertoli cells, all phases of spermatogonia and spermatocytes in male rats (23) , suggesting that PRL plays a pivotal role in the development of spermatogenesis. In addition, several older studies on animals demonstrated that normal serum PRL levels are required for a normal testicular function and growth of accessory sex organs, since PRL acts synergistically with LH and testosterone (24, 25) and it regulates the levels of the testosterone precursors for conversion under the in¯uence of LH (25) . On the other hand, hyperprolactinemia suppressed LH pulse frequency in castrated male rats (26) and decreased testosterone levels by inhibiting gonadotropin-releasing hormone and, consequently, gonadotropin secretion in men (27) . Thus, hyperprolactinemia affects male gonadal function, acting at different levels. As a consequence, hyperprolactinemia affects seminal¯uid quality through many different mechanisms, in particular causing spermiogenic arrest and impairing sperm motility and/or quality. This induces cytological ®ndings of sperm characteristics similar to that observed in the prepubertal testis (2). The rapid normalization of gonadotropin and testosterone secretion improved either sperm maturation or the function of the accessory glands that are under the direct action of EUROPEAN 
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Gonadal function in hyperprolactinemic males 291 Figure 3 Serum DHT pro®les in the seven patients before and after CAB treatment (upper panel) and in the ten patients before and after BRC treatment (lower panel). Table 3 Rigiscan analysis in 17 males with prolactinoma during chronic treatment with cabergoline or bromocriptine. The nocturnal penile tumescence is expressed as best record of the number of episodes/night. 7  0  0  1  3  8  0  0  1  3  9  0  0  1  3  10  0  0  1  3 testosterone. In fact, integrity of gonadotroph function is likely required to obtain the recovery of gonadal function after PRL suppression. It was suggested that gonadal dysfunction in males with prolactinoma could turn from functional modi®cation into irreversible damage in patients with large tumors and severe testosterone de®ciency (28) . The improvement of NPT results, libido and potency (earlier in patients treated with CAB than in those treated with BRC) clearly demonstrated that hyperprolactinemia in¯uences male sexual function.
Follow-up
In conclusion, the results of this study show that treatment with CAB for 6 months is successful in normalizing serum PRL levels and in rapidly restoring gonadal function in men with prolactinoma, with an excellent tolerability. Thus, CAB could be successfully employed in the treatment of male hyperprolactinemic hypogonadism.
